John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

By embracing biohacking trends strategically and ethically, brands can position themselves as leaders in the wellness ...

Today, Uncle Sam’s foot is almost exclusively stomping on emerging biotechnology’s brakes, is only tepidly engaged with the accelerator, and is still hands off the wheel. A new Congress and ...

biotech ETFs offer a strategic investment option. Emerging biotech firms can be highly rewarding investments, but they also carry significant risk due to regulatory hurdles and market competition.

The emerging biotech's first commercial vaccine, for covid, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

Strategic investments in emerging biotech companies offer long-term upside, but also expose Innoviva to volatile swings in valuation that could compromise financial stability. Continuing to invest ...